부산대학교 도서관

The patient showed no response to hydrocortisone (500 mg X 3 days,300 mg X 3 days,100 mg X 3 days), adenosine triphosphate (240 mg/day), and urokinase (60,000 IU X 6 days). There was a history of brainstem infarction, polycythemia was noted and a diagnosis of multiple brain infarction was made by MRI. When a thromboxane A2 synthesis inhibitor was administered, the mean hearing improved markedly from 82.5 dB to 41.25 dB. Inhibition of thromboxane A2 production was considered to have induced suppression of platelet aggregation and vasodilation and, thus, increased the blood flow to the inner ear. Thromboxane A2 inhibitors are usually used in the treatment of cerebral infarction. Their effectiveness in acute sensorineural deafness should be further evaluated.